Advisor Group’s Denali Therapeutics DNLI Stock Holding History

Advisor Group’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$17K	Hold	993	–	–	﹤0.01%	4040
2019 Q3	$15K	Buy	993 +243	+32%	+$4.64K	﹤0.01%	4117
2019 Q2	$16K	Buy	+750	New	+$16.8K	﹤0.01%	4100

Other funds holding DNLI

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Advisor Group's DNLI Position: Q4 2019 in Review

Advisor Group held its Denali Therapeutics (DNLI) position steady in Q4 2019 at 993 shares worth $17K. The position accounts for ﹤0.01% of the portfolio, ranked #4040.

Advisor Group first reported a position in DNLI in Q2 2019 and has held it in 3 quarters since. 108 funds tracked by Wall St. Rank hold DNLI as of Q4 2019.

Advisor Group held 993 shares of Denali Therapeutics worth $17K as of Q4 2019.
Advisor Group left its Denali Therapeutics share count unchanged in Q4 2019.
Denali Therapeutics made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #4040 holding.
Advisor Group first reported a position in Denali Therapeutics in Q2 2019 and has held it in 3 quarters since.
108 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.